Uwell Biopharma Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2018
Period Ending	Apr '26 Apr 27, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2018
Debt / Equity Ratio	0.01	0.08	0.08	0.18	0.14	0.29	Upgrade
Net Debt / Equity Ratio	-0.95	-0.66	-0.74	-0.42	-0.63	-0.33	Upgrade
Net Debt / EBITDA Ratio	4.16	1.06	1.71	0.41	1.16	0.49	Upgrade
Net Debt / FCF Ratio	5.39	1.32	1.83	0.54	1.26	0.35	Upgrade
Asset Turnover	-	0.01	-	-	-	-	Upgrade
Quick Ratio	14.12	4.48	9.52	2.83	6.28	3.68	Upgrade
Current Ratio	14.15	4.53	9.61	2.90	6.68	3.99	Upgrade
Return on Equity (ROE)	-	-48.06%	-59.77%	-62.47%	-69.31%	-51.33%	Upgrade
Return on Assets (ROA)	-	-27.88%	-33.99%	-37.52%	-33.39%	-27.06%	Upgrade
Return on Capital Employed (ROCE)	-24.10%	-66.30%	-44.40%	-98.90%	-52.00%	-57.00%	Upgrade
Buyback Yield / Dilution	-105.26%	-31.62%	-55.95%	-141.86%	-11.16%	-28.48%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.